Physician profile
Ernest Afflu
NPI 1447294764
$13,518.52
in general payments reported to CMS, 2019-2025
36 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,987 · 2020: $1,048 · 2021: $1,215 · 2022: $1,435 · 2023: $1,667 · 2024: $1,819 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,812 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,812.48 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,968.16 | 2019-2024 | Latitude Communicator Power Supply, Resonate El Icd Vr, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $1,196.65 | 2019-2025 | |
| Medtronic Vascular, INC. | $1,128.60 | 2019-2020 | |
| Lilly USA, LLC | $1,042.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $1,035.95 | 2019-2025 | Aveir, Jot Dx, Tendril |
| Merck Sharp & Dohme LLC | $952.25 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Janssen Pharmaceuticals, INC | $870.12 | 2019-2024 | Xarelto |
| Amgen INC. | $622.09 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $552.20 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $473.89 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $391.09 | 2021-2023 | Mycarelink |
| E.R. Squibb & Sons, L.L.C. | $389.07 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $377.89 | 2019-2024 | Lifevest |
| Biotronik INC. | $341.12 | 2019-2022 | |
| Pfizer INC. | $270.41 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $255.30 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $253.65 | 2019-2021 | |
| Viiv Healthcare Company | $218.94 | 2019-2025 | Dovato |
| Scpharmaceuticals INC. | $172.03 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $156.59 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $154.42 | 2019-2023 | Amvuttra |
| Abiomed | $111.19 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $95.24 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $89.36 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $81.12 | 2024 | Assure Wcd |
| Janssen Biotech, INC. | $56.66 | 2023 | Symtuza |
| Glaxosmithkline, LLC. | $44.99 | 2021-2025 | Shingrix |
| Gilead Sciences, INC. | $42.78 | 2020-2023 | |
| Acarix USA INC. | $29.09 | 2022 | |
| Cardiva Medical, INC. | $26.30 | 2021 | |
| Medtronic Minimed, INC. | $26.13 | 2019 | |
| Qiagen, LLC | $21.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| Bardy Diagnostics, INC. | $19.92 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.05 | 2021 | |
| Shield Therapeutics INC | $13.92 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Afflu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.